Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

CGEN

Compugen Ltd

May 23 • 04:00PM ET

2.27

Dollar change -0.07
Percentage change -2.99	%

Healthcare • Biotechnology • Israel • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: GWX SPDW

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	5.38%	Shs Outstand	89.24M	Perf Week	6.07%
Market Cap	203.23M	Forward P/E	-	EPS next Y	-0.06	Insider Trans	0.00%	Shs Float	84.72M	Perf Month	18.85%
Income	-16.68M	PEG	-	EPS next Q	-0.09	Inst Own	15.68%	Short Float	2.30%	Perf Quarter	-2.99%
Sales	36.02M	P/S	5.64	EPS this Y	25.40%	Inst Trans	-29.75%	Short Ratio	3.85	Perf Half Y	242.95%
Book/sh	0.67	P/B	3.41	EPS next Y	63.83%	ROA	-16.85%	Short Interest	1.95M	Perf Year	176.49%
Cash/sh	1.13	P/C	2.01	EPS next 5Y	-	ROE	-25.89%	52W Range	0.53 - 3.03	Perf YTD	14.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.14%	ROI	-26.75%	52W High	-25.08%	Beta	2.73
Dividend TTM	-	Quick Ratio	4.29	Sales past 5Y	94.22%	Gross Margin	88.60%	52W Low	328.30%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	4.29	EPS Y/Y TTM	50.81%	Oper. Margin	-31.51%	RSI (14)	55.42	Volatility	15.70% 8.39%
Employees	68	Debt/Eq	0.05	Sales Y/Y TTM	380.24%	Profit Margin	-46.32%	Recom	1.00	Target Price	4.00
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	24.68%	Payout	-	Rel Volume	2.13	Prev Close	2.34
Sales Surprise	5.53%	EPS Surprise	27.27%	Sales Q/Q	-	Earnings	May 20 BMO	Avg Volume	505.75K	Price	2.27
SMA20	10.46%	SMA50	1.80%	SMA200	43.13%	Trades		Volume	1,078,300	Change	-2.99%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-22	Downgrade	Jefferies	Buy → Hold	$2
May-26-20	Resumed	JMP Securities	Mkt Outperform	$18
May-13-20	Initiated	Stifel	Buy	$19
May-07-20	Initiated	SVB Leerink	Outperform
Apr-22-20	Initiated	ROTH Capital	Buy	$28
Mar-24-20	Initiated	SunTrust	Buy	$16
Jan-16-20	Initiated	Cantor Fitzgerald	Overweight	$10
Mar-29-18	Initiated	Oppenheimer	Outperform
Feb-01-16	Resumed	Oppenheimer	Outperform
Oct-15-15	Initiated	FBR Capital	Outperform	$14
Apr-23-15	Resumed	Jefferies	Buy	$11
Apr-21-15	Initiated	Oppenheimer	Outperform	$11
Feb-07-14	Initiated	MLV & Co	Buy	$14
Dec-28-09	Reiterated	Cantor Fitzgerald	Buy	$5 → $12
Jul-29-09	Initiated	Cantor Fitzgerald	Buy	$6.50

Show Previous Ratings

May-21-24 08:08AM	Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +6.90%
May-20-24 11:52AM	CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -17.54%
08:10AM	Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Compugen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports First Quarter 2024 Results (PR Newswire)
07:00AM	Loading…
May-16-24 07:00AM	Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential (PR Newswire)
May-15-24 09:57AM	Compugen Names David Silberman CFO (MT Newswires) +5.74%
07:00AM	Compugen Appoints David Silberman as Chief Financial Officer (PR Newswire)
May-06-24 07:00AM	Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 (PR Newswire)
Apr-25-24 07:00AM	Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 (PR Newswire)
Apr-10-24 07:00AM	Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 (PR Newswire)
Apr-03-24 07:00AM	Compugen to Participate in Two Upcoming Investor Conferences (PR Newswire)
Mar-12-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice (Zacks)
Mar-11-24 07:00AM	Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy (PR Newswire) -5.44%
Mar-07-24 09:41AM	Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Loading…
Mar-06-24 07:00AM	Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 (PR Newswire)
Mar-05-24 11:53AM	CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -13.56%
07:16AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Fourth Quarter and Full Year 2023 Results (PR Newswire)
Feb-29-24 08:58AM	Is a Surprise Coming for Compugen (CGEN) This Earnings Season? (Zacks)
Feb-26-24 07:00AM	Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 (PR Newswire) +9.40%
Feb-21-24 12:00PM	Compugen (CGEN) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-20-24 07:00AM	Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 (PR Newswire)
Feb-15-24 07:00AM	Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer (PR Newswire)
Jan-08-24 07:05AM	Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer (PR Newswire) +6.86%
07:00AM	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Dec-19-23 10:11AM	Why Is Compugen (CGEN) Stock Up 189% Today? (InvestorPlace) +173.97%
07:10AM	Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer (PR Newswire)
07:05AM	Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology (PR Newswire)
07:00AM	Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program (Business Wire)
08:17AM	Loading…
Dec-15-23 08:17AM	7 Promising Penny Stocks With the Potential to Defy Expectations (InvestorPlace)
Dec-05-23 09:40AM	Is Compugen (CGEN) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-08-23 04:41PM	Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.93%
Nov-07-23 07:28AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance) -5.85%
07:00AM	Compugen Reports Third Quarter 2023 Results (PR Newswire)
Nov-06-23 07:00AM	Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy (PR Newswire)
Nov-03-23 04:35PM	Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Oct-31-23 09:00AM	Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer (PR Newswire) +10.95%
Oct-24-23 07:00AM	Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023 (PR Newswire) +6.44%
Oct-03-23 07:00AM	Compugen to Present at Single Cell Genomics 2023 Meeting (PR Newswire)
Oct-02-23 07:00AM	Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer (PR Newswire)
Sep-27-23 09:00AM	Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023 (PR Newswire)
Sep-14-23 09:40AM	Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-31-23 07:00AM	Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-29-23 09:40AM	Has Compugen (CGEN) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-10-23 12:13PM	Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:17AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance) -8.04%
07:00AM	Compugen Reports Second Quarter 2023 Results (PR Newswire)
Jul-24-23 07:00AM	Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023 (PR Newswire) -5.88%
Jul-17-23 07:00AM	Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party (PR Newswire)
Jun-22-23 07:00AM	Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study (PR Newswire) -7.89%
Jun-13-23 07:00AM	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Jun-05-23 07:00AM	Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer (PR Newswire) +6.67%
Jun-02-23 07:09AM	We Think Compugen (NASDAQ:CGEN) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey)
May-18-23 09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
May-15-23 07:10AM	Compugen: Q1 Earnings Snapshot (AP Finance) +10.02%
07:00AM	Compugen Reports First Quarter 2023 Results (PR Newswire)
May-11-23 07:00AM	Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023 (PR Newswire)
May-09-23 07:00AM	Compugen to Present at the JMP Securities Life Sciences Conference (PR Newswire)
May-01-23 07:00AM	Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023 (PR Newswire)
Apr-27-23 07:00AM	Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023 (PR Newswire)
Apr-26-23 07:00AM	Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting (PR Newswire)
Mar-15-23 07:00AM	Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023 (PR Newswire)
Mar-14-23 09:40AM	Is Certara (CERT) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-13-23 06:30AM	Compugen (NASDAQ:CGEN investor three-year losses grow to 90% as the stock sheds US$11m this past week (Simply Wall St.)
Mar-10-23 02:08AM	Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 07:00AM	Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-06-23 07:00AM	Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study (PR Newswire)
Feb-28-23 12:17PM	Why Compugen Shares Are Up Today (Motley Fool)
Feb-27-23 07:00AM	Compugen Reports Fourth Quarter and Full Year 2022 Results (PR Newswire)
Feb-14-23 07:00AM	Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3 (PR Newswire) +6.29%
Feb-13-23 07:00AM	Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023 (PR Newswire)
Feb-09-23 07:00AM	Compugen to Present at the SVB Securities Global Biopharma Conference (PR Newswire) -6.32%
Feb-08-23 05:25PM	Why Compugen Stock Got Slammed Today (Motley Fool) -10.30%
Jan-27-23 09:32AM	12 Best One Dollar Stocks to Buy According To Hedge Funds (Insider Monkey)
Jan-23-23 07:00AM	Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview (PR Newswire)
Dec-29-22 04:53PM	Why Shares of Compugen Rose on Thursday (Motley Fool)
Dec-06-22 07:00AM	Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer (PR Newswire)
Dec-01-22 07:00AM	Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients (PR Newswire) -5.83%
Nov-30-22 04:49PM	Why Shares of Compugen Rose 16.5% on Wednesday (Motley Fool) +16.50%
Nov-29-22 07:00AM	Compugen to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-17-22 04:51PM	Why Shares of Compugen Jumped 17.86% on Thursday (Motley Fool) +17.86%
Nov-16-22 07:00AM	Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific (PR Newswire)
Nov-14-22 06:52PM	Why Compugen Stock Crumbled Today (Motley Fool) -9.27%
07:00AM	Compugen Reports Third Quarter 2022 Results (PR Newswire)
Nov-08-22 07:00AM	Compugen to Participate in the Stifel Healthcare Conference (PR Newswire)
Nov-07-22 08:00AM	Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients (PR Newswire)
08:00AM	Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients (PR Newswire)
Nov-02-22 07:00AM	Compugen Announces Receipt of Nasdaq Delisting Notice (PR Newswire) -11.60%
Nov-01-22 04:41PM	Why Shares of Compugen Jumped 9.27% on Tuesday (Motley Fool) +9.27%
Oct-31-22 07:00AM	Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022 (PR Newswire) +8.78%
Oct-26-22 07:00AM	Compugen to Present New Clinical Data at ESMO-IO (PR Newswire) +6.80%
Oct-06-22 07:00AM	Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 (PR Newswire)
Sep-22-22 07:00AM	Compugen Letter to Shareholders (PR Newswire) -10.57%
Sep-12-22 07:00AM	Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer (PR Newswire)
Sep-07-22 07:00AM	Compugen to Participate in Upcoming Fierce Biotech Summit (PR Newswire)
Sep-01-22 02:32PM	Shareholders in Compugen (NASDAQ:CGEN) are in the red if they invested a year ago (Simply Wall St.)
Aug-24-22 07:00AM	Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan (PR Newswire)
Aug-08-22 07:00AM	Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio (PR Newswire)

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEN

Compugen Ltd

Upgrade your FINVIZ experience